This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 2 EPO patents. Top assignee: Almac House. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: Graham Trevitt: Innovator in Cancer Treatment
Introduction
Graham Trevitt is a notable inventor based in Craigavon, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cancer treatment.
Latest Patents
One of his key patents is titled "Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors." This invention relates to compounds that inhibit the activity of Wee-1 kinase, which plays a crucial role in cell cycle regulation. The patent also encompasses pharmaceutical compositions that include these compounds and outlines methods for using them in cancer treatment.
Career Highlights
Throughout his career, Graham has worked with prominent organizations such as Almac House and Almac Discovery Limited. His work in these companies has been instrumental in advancing research and development in the pharmaceutical industry.
Collaborations
Graham has collaborated with notable professionals in his field, including Andrew John Wilkinson and Steven D Shepherd. These partnerships have contributed to the success of his projects and innovations.
Conclusion
Graham Trevitt's work in developing innovative cancer treatments through his patented compounds showcases his dedication to improving healthcare. His contributions continue to impact the pharmaceutical landscape positively.